Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Biotricity is a medical device company specializing in remote cardiac monitoring solutions, primarily through its Bioflux and Biotres platforms for continuous ECG monitoring. The company operates in the fragmented cardiac telemetry market, competing against established players like iRhythm and BioTelemetry (now Philips), with differentiation through proprietary AI-driven diagnostic algorithms and a direct-to-physician sales model. The business is pre-profitability with 76.6% gross margins indicating strong unit economics once scale is achieved, but currently burning cash with negative operating margins of -17.8%.
Biotricity generates revenue through a hybrid model: upfront device sales to healthcare providers and recurring monthly monitoring fees per patient. The company bills Medicare, Medicaid, and commercial insurers using CPT codes for cardiac event monitoring (93228-93229 series). Competitive advantages include proprietary AI algorithms for arrhythmia detection that reduce false positives, cellular-enabled devices eliminating patient compliance issues with traditional Holter monitors, and a direct sales force targeting cardiology practices and hospitals. The 76.6% gross margin suggests strong pricing power once R&D and SG&A are absorbed, but current scale limitations prevent profitability. Revenue is highly dependent on physician adoption rates and reimbursement policy stability.
Monthly active monitoring patient count and net patient additions (key leading indicator of recurring revenue trajectory)
Medicare reimbursement rate changes for remote cardiac monitoring CPT codes (CMS fee schedule updates)
New hospital or integrated delivery network (IDN) contract announcements with disclosed patient volume potential
FDA clearance announcements for expanded device indications or new monitoring modalities
Quarterly cash burn rate and runway to profitability or need for dilutive equity raises
Medicare reimbursement rate compression for remote monitoring services as CMS seeks cost containment, with potential 5-10% cuts in 2027-2028 reimbursement cycles threatening unit economics
Technological obsolescence risk as larger competitors (Apple Watch ECG, Samsung health monitoring) integrate consumer-grade cardiac monitoring into wearables, potentially commoditizing basic arrhythmia detection
Regulatory pathway changes requiring more extensive clinical validation for AI-driven diagnostic algorithms, increasing time-to-market and development costs for product enhancements
Market share loss to well-capitalized incumbents (iRhythm with $400M+ annual revenue, Philips BioTelemetry) that can offer bundled monitoring solutions and deeper hospital system integration
Pricing pressure from new entrants and private equity-backed consolidation in cardiac monitoring space, compressing gross margins below current 76.6% as market matures
Physician adoption barriers due to workflow integration challenges and preference for established monitoring platforms with proven clinical validation
Critical liquidity crisis indicated by 0.21 current ratio and negative operating cash flow, suggesting immediate need for capital raise within 3-6 months to avoid going concern issues
Negative book value (Price/Book of -0.2x) and negative equity position limiting access to traditional debt financing, forcing reliance on dilutive equity or convertible instruments
High cash burn rate relative to $0.0B market cap creates significant dilution risk for existing shareholders, with potential 50-100% share count increase needed to fund operations through 2027
low - Healthcare spending, particularly for chronic disease management and cardiac monitoring, is relatively recession-resistant as procedures are medically necessary rather than discretionary. However, the company faces indirect cyclical pressure through hospital capital budgets (device purchases) and potential delays in elective cardiology procedures during economic downturns. Medicare and Medicaid reimbursement provides stable demand base representing estimated 65-70% of cardiac monitoring market. The primary macro sensitivity is through healthcare provider financial health rather than direct consumer spending patterns.
Rising interest rates create multiple headwinds: (1) Higher discount rates compress valuation multiples for pre-profitable growth companies, particularly acute for BTCY given negative cash flows; (2) Increased cost of capital for potential debt financing, though company currently relies on equity; (3) Hospital systems face higher borrowing costs for capital equipment purchases, potentially delaying device adoption. The 0.21 current ratio indicates severe liquidity constraints, making access to capital markets critical. In higher rate environments, equity raises become more dilutive as growth stock valuations contract.
Moderate credit exposure through two channels: (1) Accounts receivable risk from hospital systems and physician practices, with typical 60-90 day payment cycles creating working capital strain given negative operating cash flow; (2) Reimbursement risk from commercial insurers during credit tightening, as payers may delay payments or increase prior authorization requirements. The -0.43 debt-to-equity ratio (negative equity) indicates the company is not currently servicing traditional debt, but severe liquidity constraints (0.21 current ratio) suggest potential need for expensive bridge financing or factoring arrangements if credit markets tighten.
speculative growth - The stock attracts high-risk tolerance investors seeking asymmetric upside in early-stage medical device plays, despite severe financial distress signals. The -62.6% one-year return and -50.7% three-month decline indicate capitulation by institutional holders, leaving primarily retail speculators and distressed/special situations funds. Not suitable for value investors given negative book value, nor income investors given no dividend and cash burn. The 66.9% EPS growth is misleading given negative absolute earnings; improvement reflects reduced losses rather than profitability inflection.
high - Micro-cap medical device stocks with sub-$10M market caps, negative cash flows, and binary clinical/regulatory catalysts exhibit extreme volatility. Recent 50%+ quarterly declines suggest beta well above 2.0x. Stock is highly susceptible to dilution events, FDA announcements, and reimbursement policy changes. Illiquidity amplifies price swings on low volume. Appropriate only for portfolio allocations under 1-2% given potential for total loss if financing cannot be secured.